Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting
Alterity Therapeutics is today releasing interim clinical data of its Phase 1 clinical trial program for its investigative drug PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA.
Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting
Alterity Therapeutics will present clinical data from its lead drug candidate PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA, from 5-9th May 2019.
Alterity Therapeutics Investor Presentation
Alterity Therapeutics Launches to Asian Investors
Alterity Therapeutics Limited, (formerly Prana Biotechnology Limited) is meeting this week with sophisticated investors in both Singapore and Hong Kong in the first leg of a global investor roadshow.
Change of Company Name
We wish to announce the Company name change has been processed by the Australian Securities and Investment Commission and the Company has changed its name from “Prana Biotechnology Limited” to “Alterity Therapeutics Limited”.
Completion of investment by Life Biosciences LLC and capital raising update
Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) (ASX:PBT) (“Alterity” or “the Company”) is pleased to announce completion of the strategic investment by Life Biosciences LLC (Life) of an initial US$7.5m (A$10.526m at an exchange rate of A$1.00 to US$0.7125) in the Company (Subscription).
Results of General Meeting
The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried on a show of hands.
Prana EGM and Conference Call Facility
Prana Biotechnology today advises that a conference call facility will be available at the Extraordinary General Meeting (EGM) scheduled for Friday, April 5, 2019, at 11:00 AM AEDT.
Prana receives A$3.3 million R&D Tax Incentive
Prana has today announced that is has received a A$3.3 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.